DRUG ELUTING STENTS MARKET ANALYSIS

Drug Eluting Stents Market, By Product Type (Polymer-based Coatings, Polymer free Coatings (Micro porous Surface, Micro structured Surface, Slotted Tubular Surface, and Nanoporous Surface), By Application (Coronary Artery Disease, Peripheral Artery Disease, and Others), By End User (Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jan 2025
Code : CMI566
Pages :150
Formats :
Excel and PDF
Industry : Medical Devices

The global drug eluting stents market has significant growth potential over the forecast period driven by an increasing prevalence of cardiovascular diseases and rising geriatric population globally. The market currently faces some restraints due to the high cost of drug eluting stents compared to bare-metal stents which may limit adoption in some price-sensitive markets. However, ongoing technological advancements focused on developing innovative drug eluting stent designs with enhanced efficacy and reduced healing times are expected to drive market expansion.
Among regions, North America will likely continue dominating the market, supported by well-established healthcare systems and high patient acceptance of advanced technologies. Asia Pacific offers lucrative opportunities and is poised to emerge as the fastest-growing regional market. This can be attributed to growing medical tourism, rising healthcare spending, and increasing focus of key players on expanding their distribution networks in countries with large patient pools like China and India.
The bioresorbable stents segment may witness increased adoption over the forecast period on account of associated advantages such as reduced long-term risks and requirement of lesser dual antiplatelet therapy duration. Additionally, favorable reimbursement reforms are projected to boost the market across several developing Asian and Latin American countries. However, maintaining a sizable revenue share, durable polymer-based drug eluting stents are expected to continue dominating the market in the short to mid-term.